Jalon Therapeutics

Jalon Therapeutics is a biotechnology company headquartered in Paris, France, specializing in researching new methods to induce cancer cell death. Co-founded in 2021 by Jean-Luc Poyet, Professor Martine Bagot, Professor Hervé Dombret, Jérôme Tiollier, Jean-Christophe Rain, and Philippe Salphati, and led by CEO David Loison, the company aims to develop innovative therapies targeting key oncogenic signaling pathways. To achieve this, the company leverages its deep understanding of stress-related protein-protein interaction networks that sustain malignant phenotypes but are not essential for normal cells. This mechanism, defined as "non-oncogene addiction" (NOA), offers potential novel, safer, and more effective therapeutic strategies.